Lipoprotein(a) Levels and the Risk of Coronary Heart Disease and Stroke: The Suita Study.

IF 3 2区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of atherosclerosis and thrombosis Pub Date : 2025-03-30 DOI:10.5551/jat.65437

Ahmed Arafa, Yuka Kato, Yoshihiro Kokubo, Paramita Khairan, Chisa Matsumoto, Yoko M Nakao, Yu Kataoka, Mariko Harada-Shiba

{"title":"Lipoprotein(a) Levels and the Risk of Coronary Heart Disease and Stroke: The Suita Study.","authors":"Ahmed Arafa, Yuka Kato, Yoshihiro Kokubo, Paramita Khairan, Chisa Matsumoto, Yoko M Nakao, Yu Kataoka, Mariko Harada-Shiba","doi":"10.5551/jat.65437","DOIUrl":null,"url":null,"abstract":"Aims: Lipoprotein(a) (Lp[a]) exhibits atherogenic and thrombogenic properties. We investigated the association between Lp(a) levels and the risk of coronary heart disease (CHD) and stroke.Methods: We used data from 5138 people ≥ 30 years old registered in the Suita Study, a Japanese population-based prospective cohort study. All participants were initially free from CHD or stroke. Cox proportional hazard models were applied to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for CHD and stroke among participants with elevated Lp(a) levels.Results: At baseline, only 17.0% of participants had Lp(a) levels ≥ 30 mg/dL. Within the median follow-up period of 11.7 years, 164 CHD and 234 stroke events were detected. In the multivariable-adjusted regression model, Lp(a) ≥ 30 mg/dL was associated with an increased risk of CHD (HR, 1.52 [95% CI, 1.05-2.21]). Every 10-ml/dL increment in Lp(a) level was associated with a 7.9% increase in CHD risk. The association with CHD did not change significantly after adjusting for total cholesterol level or lipid-lowering drugs. In contrast, increased Lp(a) levels were not associated with stroke risk or any subtype.Conclusions: Lp(a) ≥ 30 mg/dL was associated with an increased risk of CHD in the Japanese population.","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of atherosclerosis and thrombosis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5551/jat.65437","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: Lipoprotein(a) (Lp[a]) exhibits atherogenic and thrombogenic properties. We investigated the association between Lp(a) levels and the risk of coronary heart disease (CHD) and stroke.

Methods: We used data from 5138 people ≥ 30 years old registered in the Suita Study, a Japanese population-based prospective cohort study. All participants were initially free from CHD or stroke. Cox proportional hazard models were applied to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for CHD and stroke among participants with elevated Lp(a) levels.

Results: At baseline, only 17.0% of participants had Lp(a) levels ≥ 30 mg/dL. Within the median follow-up period of 11.7 years, 164 CHD and 234 stroke events were detected. In the multivariable-adjusted regression model, Lp(a) ≥ 30 mg/dL was associated with an increased risk of CHD (HR, 1.52 [95% CI, 1.05-2.21]). Every 10-ml/dL increment in Lp(a) level was associated with a 7.9% increase in CHD risk. The association with CHD did not change significantly after adjusting for total cholesterol level or lipid-lowering drugs. In contrast, increased Lp(a) levels were not associated with stroke risk or any subtype.

Conclusions: Lp(a) ≥ 30 mg/dL was associated with an increased risk of CHD in the Japanese population.

查看原文本刊更多论文

脂蛋白（a）水平与冠心病和中风的风险：水田研究

目的：脂蛋白(a) （Lp[a]）具有致动脉粥样硬化和血栓形成的特性。我们调查了Lp(a)水平与冠心病（CHD）和中风风险之间的关系。方法：我们使用的数据来自5138名≥30岁的日本人群前瞻性队列研究——Suita研究。所有参与者最初都没有冠心病或中风。应用Cox比例风险模型计算Lp(a)水平升高的受试者冠心病和卒中的风险比（hr）和95%置信区间（ci）。结果：基线时，只有17.0%的参与者Lp(a)水平≥30mg /dL。在中位随访11.7年期间，检测到164例冠心病和234例卒中事件。在多变量校正回归模型中，Lp(a)≥30 mg/dL与冠心病风险增加相关（HR, 1.52 [95% CI, 1.05-2.21]）。Lp(a)水平每增加10ml /dL，冠心病风险增加7.9%。在调整总胆固醇水平或降脂药物后，与冠心病的关系没有显著改变。相反，增高的Lp(a)水平与卒中风险或任何亚型无关。结论：在日本人群中，Lp(a)≥30 mg/dL与冠心病风险增加相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊